Vericel Co. (NASDAQ:VCEL) CEO Sells $724,150.00 in Stock

Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the transaction, the chief executive officer now owns 220,937 shares in the company, valued at $9,142,373.06. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Vericel Stock Up 2.4 %

NASDAQ VCEL traded up $0.99 on Friday, hitting $41.66. The company’s stock had a trading volume of 250,030 shares, compared to its average volume of 430,068. Vericel Co. has a 1-year low of $32.28 and a 1-year high of $54.10. The company’s 50-day moving average is $45.34 and its 200 day moving average is $46.81. The firm has a market cap of $2.02 billion, a PE ratio of -4,067.00 and a beta of 1.67.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). Vericel had a net margin of 0.37% and a return on equity of 0.35%. The firm had revenue of $52.70 million during the quarter, compared to analysts’ expectations of $52.59 million. During the same period in the prior year, the company posted ($0.11) EPS. The company’s revenue was up 14.8% on a year-over-year basis. On average, equities analysts expect that Vericel Co. will post 0.12 EPS for the current year.

Hedge Funds Weigh In On Vericel

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. MCF Advisors LLC increased its position in shares of Vericel by 86.1% during the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock worth $25,000 after buying an additional 223 shares during the period. CWM LLC increased its position in shares of Vericel by 319.0% during the second quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock worth $30,000 after buying an additional 504 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Vericel by 9.7% during the second quarter. Nisa Investment Advisors LLC now owns 2,484 shares of the biotechnology company’s stock worth $114,000 after buying an additional 220 shares during the period. Lazard Asset Management LLC increased its position in shares of Vericel by 178.7% during the first quarter. Lazard Asset Management LLC now owns 2,584 shares of the biotechnology company’s stock worth $134,000 after buying an additional 1,657 shares during the period. Finally, RiverPark Advisors LLC acquired a new stake in shares of Vericel during the first quarter worth $147,000.

Analyst Ratings Changes

Several analysts recently commented on VCEL shares. Canaccord Genuity Group started coverage on shares of Vericel in a report on Friday, August 9th. They set a “buy” rating and a $57.00 target price for the company. StockNews.com downgraded shares of Vericel from a “hold” rating to a “sell” rating in a report on Tuesday, October 8th. Canaccord Genuity Group started coverage on shares of Vericel in a report on Friday, August 9th. They issued a “buy” rating and a $57.00 price objective for the company. Stephens boosted their price objective on shares of Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Finally, TD Cowen boosted their price objective on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, August 27th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Vericel has a consensus rating of “Moderate Buy” and a consensus price target of $57.71.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.